Novavax's COVID-19 vaccine study generated a promising immune response in an early-stage clinical trial in results unveiled Tuesday, reports The Wall Street Journal.
The company has never brought a vaccine to market in its 33-year history but received a $1.6 billion grant from the government's Operation Warp Speed to have 100 million doses ready by early 2021.
The phase one trial included 131 healthy participants between the ages of 18 and 59 at two sites in Australia.
Novavax, of Maryland, said the vaccine was "well-tolerated and had a reassuring safety profile" and provoked an immune response with higher levels of antibodies in people who received the vaccine than in people who had recovered from coronavirus. Scientists mixed stable, prefusion protein with a compound called adjuvant to improve the performance of the vaccine.
Some participants reported mild effects such as fatigue, muscle aches, and headaches.
"The Phase 1 data demonstrate that NVX-CoV2373 with our Matrix-M adjuvant is a well‑tolerated COVID-19 vaccine with a robust immunogenicity profile," Gregory Glenn, president for research and development at Novavax, said in a statement Tuesday.
Novovax (NVAX) is slated to start a 30,000-person final-stage study in the fall which will test whether the immune responses triggered by the vaccine safely protect people from the coronavirus.
More than 4.7 million people have been infected with COVID-19 in the U.S. and at least 155,000 have died.
© 2021 Newsmax. All rights reserved.